The identification and optimization of orally efficacious, small molecule VLA-4 antagonists

Current Topics in Medicinal Chemistry

Volumn 4, Issue 14, 2004, Pages 1473-1484

  Huryn, Donna M ^a   Konradi, Andrei W ^b   Ashwell, Susan ^a,c   Freedman, Stephen B ^b   Lombardo, Louis J ^a,d   Pleiss, Michael A ^b   Thorsett, Eugene D ^b,e   Yednock, Ted ^b   Kennedy, Jeffrey D ^a  

^a PFIZER INC   (United States)

^b ELAN PHARMACEUTICALS   (United States)

^c ASTRAZENECA   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

^e Icos Pharmaceuticals   (United States)

Author keywords

Asthma; Cell adhesion; Multiple sclerosis; Pro drug; VLA 4 antagonist

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; EPITOPE; FIBRONECTIN; IMMUNOGLOBULIN G; NATALIZUMAB; NEUTRALIZING ANTIBODY; PHENYLALANINE DERIVATIVE; PROLINE DERIVATIVE; SULFONAMIDE; TRIPEPTIDE DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ASTHMA; CELL ADHESION; CELL ASSAY; CLINICAL TRIAL; CROHN DISEASE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENTERITIS; HUMAN; IN VITRO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PHARMACOPHORE; PROCESS OPTIMIZATION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ASTHMA; CELL ADHESION; DIPEPTIDES; HUMANS; INTEGRIN ALPHA4BETA1; MULTIPLE SCLEROSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4844230170     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387467     Document Type: Review

References (36)

1. Elices, M. Natalizumab Elan. Curr. Opin. Anti-Inflamm. Immunomodulatory Invest. Drugs 2000, 2, 228-235.
2. Ysuf-Makagiansar, H.; Anderson, M.E.; Yakovleve, T.V.; Murray, J.S.; Siahaan, T.J. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases. Medicinal Research Review 2002, 22, 146-147.
3. 1. Cell Adhesion Comm. 1996, 3, 487-495.
4. 1). J. Cell Biol. 1994, 124, 601-608.
5. Komoriya, A.; Green, L.J.; Mervic, M.; Yamada, S.S.; Yamada, K.M.; Humphries, M.J. The Minimal Essential Sequence for a Major Cell Type-Specific Adhesion Site (CS-1) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronenctin is Leucine-Aspartic Acid-Valine. J. Biol. Chem. 1991, 266, 15075-15079.
6. Vonderheide, R.H.; Tedder, T.F.; Springer, T.A.; Staunton, D.E. Residues within a Conserved Amino Acid Motif of Domains 1 and 4 of VCAM-1 are Required for Binding to VLA-4. J. Cell Biol. 1994, 125, 215-222.
7. Hagmann, W.K.; Durette, P.L.; Lanza, T.; Kevin, N.J.; deLaszlo, S.E.; Kopka, I.E.; Young, D.; Magriotis, P.A.; Li, B.; Lin, L.S.; Yang, G.; Kamenecka, T.; Chang, J.W.; MacCoss, M.; Mills, S.G.; Van Riper, G.; McCauley, E.; Egger, L.A.; Kidambi, U.; Lyons, K.; Vincent, S.; Stearns, R.; Colletti, A.; Teffera, J.; Tong, S.; Fenyk-Melody, J.; Owens, K.; Levorse, D.; Kim, P.; Schmidt, J.A.; Mumford, R.A. The Discovery of Sulfonylated Dipeptides as Potent VLA-4 Antagonists. Bioorganic & Medicinal Chemistry Letters 2001, 11, 2709-2713.
8. Chen, L.; Tilley, J.W.; Huang, T.N.; Miklowski, D.; Trilles, R.; Guthrie, R.W.; Luk, K.; Hanglow, A.; Rowan, K.; Schwinge, V.; Wolitzky, B. N-acyl Phenylalanine Analogues as Potent Small Molecule VLA-4 Antagonists. Bioorganic & Medicinal Chemistry Letters 2000, 10, 725-727.
9. Astles, P.C.; Harris, N.V.; Morley, A.D. Diamine Containing VLA-4 Antagonists. Bioorganic & Medicinal Chemistry 2001, 9, 2195-2202.
10. Lin, K-C.; Ateeq, S. H.; Hsiung, S.H.; Chong, LT.; Zimmerman, C.N.; Castro, A.; Lee, W-C.; Hammond, C.E.; Kalkunte, S.; Chen, L-L.; Pepinsky, R.B.; Leone, D.R.; Sprague, A.G., Abraham, W.M.; Gill, A.; Lobb, R.R.; Adams, S.P. Selective Tight-Binding Inhibitors of Integrin α4β1, that Inhibit Allergic Airway Responses. J. Med. Chem. 1999, 42, 920-934.
11. Wehner, V.; Blum, H.; Kurz, M.; Stilz, U.H. Aromatic β-amino Acids as Asp-Phg Mimics in LDV Derived VLA-4 Antagonists. Synthesis 2002, 14, 2023-2036.
12. 1Integrin-mediated Cell Adhesion. J. Biol. Chem. 1993, 268, 20352-20359.
13. Ho, W-B.; Broka, C. Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo [ij]quinoline as a VLA-4 Antagonist. J. Org. Chem. 2000, 65, 6743-6748.
14. Tilley, J.W. VLA-4 Antagonists. Expert Opin. Ther. Patents 2002, 12, 7.
15. Holland, G.W.; Biediger, R.J.; Vanderslice, P. Antagonists of VLA-4. Annual Reports in Medicinal Chemistry 2002, 37, 65-74.
16. Yang, G.X.; Hagmann, W.K. VLA-4 Antagonists: Potent Inhibitors of Lymphocyte Migration. Medicinal Research Reviews 2003, 3, 369-392.
17. Pleiss, M.A.; Thorsett, E.D.; Yednock, T. Discovery of a Novel Binding Epitope for the α4 Integrin Based on Sequence Homology Between VCAM-1 and the Third Heavy Chain Complementary Determining Region of Anti-α4 Antibodies. Abstracts of Papers - 220th American Chemical Society, Washington, DC, 2000, MEDI-132.
18. 1 Integrin-Dependent Cell Adhesion is Regulated by a Low Affinity Receptor Pool that is Conformationally Responsive to Ligand. J. Biol. Chem. 1995, 270, 28740-50.
19. Semko, C. M.; Dressen, D. B.; Grant, F. S.; Konradi, A.W.; Pleiss, M. A.; Thorsett, E. D.; Freedman, S. B.; Holsztynska, E J.; Quinn, K. P.; Yednock, T. Development of CT757: A Potent and Highly Selective Small Molecule Inhibitor of VLA-4. Abstracts of Papers - 220th American Chemical Society, Washington, DC, 2000, MEDI-133.
20. Konradi, A.W.; Pleiss, M.A.; Thorsett, E.D.; Ashwell, S.; Welmaker, G.S.; Kreft, A.; Dimitrios, S.; Dressen, D.B.; Grant, F.S.; Semko, C.; Xu, Y.-Z. Heteroaryl, Heterocyclic and Aryl Compounds which Inhibit Leukocyte Adhesion Mediated By VLA-4. U.S. Pat. Appl. 2003/0139402 A1, Jul 24, 2003.
21. Keszthelyi, E.; Karlik, S.; Hyduk, S.; Rice, G.P.A.; Gordon, G.; Yednock, T.; Horner, H. Evidence for a Prolonged Role of α4 Integrin Throughout Active Experimental Allergic Encephalomyelitis. Neurology 1996, 47, 1053-59.
22. Tarayre, J.P.; Aliaga, M.; Barbara, M.; Tisseyre, N.; Vieu, S.; Tisne-Versailles, J. Model of Bronchial Allergic Inflammation in the Brown Norway Rat, Pharmacological Modulation. Int. J. Immunopharm. 1992, 14, 847-55.
23. Xiong, J-P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S.L.; Arnaout, M.A. Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand. Science 2002, 296, 151.
24. Dappen, M. S.; Dressen, D. B.; Grant, F. S.; Konradi, A. W.; Pleiss, M. A.; Semko, C. M.; Thorsett, E. D.; Freedman, S. B.; Holsztynska, E. J.; Quinn, K. P.; Ashwell, S.; Banker, A. L.; Baudy, R. B.; Bicksler, J. J.; Giberson, .I.; Leeson, P. D.; Lombardo, L. J.; Sarantakis, D. CT747: A Very Potent and Highly Selective Small Molecule Inhibitor of VLA-4 that is Metaboliccaly Stable. Abstracts of Papers - 220th American Chemical Society 2000, MEDI-135.
25. Thorsett, E. D.; Dappen, M. S.; Dressen, D. B.; Ellingboe, J. W.; Grant, F. S.; Jacobson, M.; Kincaid, S. L.; Konradi, A. W.; Kreft, A.; Lombardo, L. J.; Mann, C. W.; Nunn, D.; Pleiss, M. A.; Sabalski, J. E.; Sacchi, K.; Sarantakis, D.; Semko, C. M. CT737-A Potent and Highly Selective non C-Terminal L-Phenylalanine Inhibitor of VLA-4. Abstracts of Papers - 220th American Chemical Society 2000, MEDI-134.
26. Sarantakis, D.; Bicksler, J. J.; Cannon, C.; Dressen, D. B.; Giberson, J.; Grant, F. F.; Konradi, A.W.; Kreft, A.; Leeson, P.D.; Lombardo, L.J.; Mann, C.W.; Pleiss, M. A.; Sabalski, J. E.; Thorsett, E. D.; Vandevert, C.; Yang, C. Acylated P-amin-L-Phyenylalanines - With VLA-4/VCAM-1 Inhibitory Activity. Abstracts of Papers - 220th American Chemical Society 2000, MEDI-137.
27. Ashwell, S.; Banker, A L.; Bicksler, J. J.; Dressen, D. B.; Cannon, C.; Giberson, J.; Grant, F. F.; Konradi, A. W.; Leeson, P. D.; Lombardo, L. J.; Pleiss, M. A.; Sarantakis, D.; Thompson, T.; Thorsett, E. D.; Vandevert, C.; Yang, C. Tos-Pro-Phe-OH Based VLA-4 Antagonists: p-Amino Phe Variants Containing Urea and Amino Groups. Abstracts of Papers - 220th American Chemical Society 2000, MEDI-138.
28. Kubrak, D.; Cannon, C.; Giberson, J.; Leeson, P. D.; Mann, C. W.; Vandevert, C.; Yang, C.; Kreft, A. TOS-PRO-PHE-OH-Based VLA-4 Antagonists: p-Amino Phe Variants Containing Thiourea and Sulfonamide Groups. Abstracts of Papers - 220th American Chemical Society 2000, MEDI-139.
29. For related work see: Sarantakis, D.; Baudy, R. B.; Bicksler, J. J.; Cannon, C.; Dressen, D. B.; Giberson, J.; Grant, F. F.; Konradi, A. W.; Kreft, A.; Kubrak, D.; Leeson, P. D.; Lombardo, L. J.; Mann, C. W.; Pleiss, M. A.; Sze, J.; Thorsett, E. D.; Vandevert; Yang, C. Acylated p-Amino-L-Phenylalanines - With VLA-4/VCAM-1 Inhibitory Activity. Abstracts of Papers - 220th American Chemical Society 2000, MEDI-136.
30. Navia, M.A.; Chaturvedi, P.R. Design Principles for Orally Bioavailable Drugs. Drug Discovery Today 1996, 1, 179-189.
31. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Delivery Reviews 1997, 23, 3-25.
32. Artursson, P. Epithelial Transport of Drugs in Cell Culture. I: A Model for Studying the Passive Diffusion of Drugs over Intestinal Abosrbtive (CACO-2) Cells. J. Pharm. Sci. 1990, 79, 476-482.
33. Artursson, P.; Karlsson, J. Correlation Between Oral Drug Absorption in Human and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (CACO-2) Cells. Biochem. Biophys. Res. Comm. 1991, 175, 880-885.
34. Yednock, T.A.; Cannon, C.; Fritz, L.C.; Sanchez-Madrid, F.; Steinman, L.; Karin, N. Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against α4β1 Integrin. Nature 1992, 356, 63.
35. Palmer, E.L.; Ruegg, C.; Ferrando, R.; Pytela, R.; Sheppard, D. Sequence and Tissue Distribution of the Integrin Alpha 9 Subunit, a Novel Partner of Aeta 1 that is Widely Distributed in Epithelia and Muscle. J. Cell Biol. 1993, 123, 1289-97.
36. Abraham, W.M.; Delehunt, J.C.; Yerger, L.; Marchette, B. Characterization of a Late Phase Pulmonary Response Following Antigen Challenge in Allergic Sheep. Am. Rev. Resp. Dis. 1983, 128, 839-44.